Press Room

Over 120 volunteer advocates from across Pennsylvania, including cancer survivors, patients and caregivers, convened at the state Capitol yesterday for ‘Cancer Action Day,’ an event hosted annually by the American Cancer Society Cancer Action Network (ACS CAN). Advocates met with their state lawmakers and urged them to support policies that aid in the fight against cancer. 

According to multiple news reports, Former President Joe Biden has been diagnosed with an “aggressive” form of prostate cancer that has spread to his bones.

Volunteer advocates, including cancer survivors, patients,

Advocates with the American Cancer Society Cancer Action Network (ACS CAN) join Arizonans in mourning the loss of Rep. Raúl Grijalva, who died Thursday after complications from battling lung cancer. 

During his more than two decades of serving in Congress, Rep. Grijalva championed efforts to improve public health by advocating for the development of new health care clinics in Southern Arizona, as well as supporting efforts to increase access to care by co-sponsoring bipartisan legislation to aid in the fight against cancer. 

Today, the U.S. House passed The Full-Year Continuing Appropriations and Extensions Act, 2025. It contains no increases for federal cancer research or prevention funding and significant cuts to Congressionally Directed Medical Research Programs (CDMRP), in which cancer is the largest recipient of funds. 

Today, the Prostate-Specific Antigen Screening for High-risk Insured Men (PSA Screening for HIM) Act was introduced in the United States House of Representatives by Representatives Neal Dunn, M.D. (R-FL) and Yvette Clarke (D-NY) with Representatives Greg Murphy (R-NC) and Troy Carter (D-LA) as cosponsors.

Bipartisan legislation that would remove financial barriers to prostate cancer screening was introduced today in the U.S. Senate. Sponsored by Senators John Boozman (R-AR) and Cory Booker (D-NJ), the Prostate-Specific Antigen Screening for High-risk Insured Men (PSA Screening for HIM) Act would waive cost-sharing requirements such as deductibles, copayments and coinsurance, for prostate cancer screening tests for men with the highest risk of prostate cancer, including Black men and those with a family history of the disease.

The following is a statement from American Cancer Society Cancer Action Network (ACS CAN) New Jersey Government Relations Director Quinton Law:

“As anybody touched by the disease can tell you, cancer demands a high price. Physically, emotionally and financially, it is a draining disease where the costs can—very quickly—feel insurmountable. This is the case for patients across the cancer continuum. New Jerseyans are looking for state leaders to intervene and prevent the costs of care from trending upward and potentially trapping them in a lifetime of medical debt. Cancer patients and survivors throughout the state were heartened to hear Governor Murphy isolate affordability as a priority in his State of the State address. In the coming year, ACS CAN urges lawmakers to focus their efforts on three areas to alleviate the financial burden of disease, starting with preventing illness for a group of New Jerseyans at heightened risk of cancer: Atlantic City casino workers.

Two years after Ocean City local Jeanmarie Mason’s breast cancer returned and spread to her bones, her daughter Julie Groob also experienced a recurrence of her cervical cancer, bringing the two closer together than ever and uniting them in the fight against cancer. As volunteers with the American Cancer Society Cancer Action Network (ACS CAN), Jeanmarie and Julie were among key voices in securing a medical debt relief victory in 2024. The pair are approaching the legislative session in 2025 eager to share their stories and advance critical proposals to limit the burden of disease across the cancer continuum.

The following is a statement from American Cancer Society Cancer Action Network (ACS CAN) Pennsylvania Government Relations Director Donna Greco:

“In 2024, ACS CAN was proud to see the Pennsylvania Legislature mobilize swiftly and in a bipartisan manner to bring the promise of precision medicine to more patients. Beginning in the new year, Act 39 of 2024 will make it so that all patients who can benefit and are insured through a state-regulated health plan will receive coverage for biomarker testing, a game changer in the fight against cancer and an essential step in accessing precision medicine treatments. Pennsylvanians also secured a victory for access to care through Act 42 of 2024, the newly enacted legislation that includes telemedicine as a covered benefit in the Commonwealth.